Atrium Therapeutics Announces $50 Million Private Placement

Atrium Therapeutics, Inc. entered into a securities purchase agreement on October 7, 2026, with selected investors to raise approximately $50 million in gross proceeds. The financing, which is expected to close on or about October 9, 2026, involves the sale of common stock and pre-funded warrants.

Under the terms of the agreement, the company agreed to issue and sell 5,170,384 shares of common stock at a price of $7.93 per share. Additionally, the company issued pre-funded warrants to purchase up to 1,134,930 shares of common stock. These warrants were sold at a price of $7.929 per warrant, which is calculated as the per-share price of $7.93 less the warrant's exercise price of $0.001. The pre-funded warrants are immediately exercisable and will expire upon full exercise.

The company stated that the securities are being sold without registration under the Securities Act of 1933, relying on exemptions for transactions not involving a public offering. Concurrently with the purchase agreement, Atrium entered into a registration rights agreement requiring the company to file a registration statement with the Securities and Exchange Commission to cover the resale of the shares and warrant shares.

Leerink Partners LLC served as the lead placement agent, with Cantor Fitzgerald & Co., Barclays Capital Inc., and Wells Fargo Securities, LLC acting as additional placement agents. The investors participating in the placement include Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital, and other life sciences-focused institutional investors.

Atrium intends to use the net proceeds from the offering, combined with its existing cash and investments, to fund the development of its two lead product candidates, other research programs, working capital, and general corporate purposes. The company estimates that these combined funds will be sufficient to finance its operations through 2028. Following the completion of the offering, the company expects to have 22,276,027 shares of common stock outstanding.